Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IONIS-FGFR4Rx
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
IONIS-FGFR4Rx is an antisense oligonucleotide drug developed to target and inhibit fibroblast growth factor receptor 4 (FGFR4). Its mechanism of action involves antagonizing FGFR4, a receptor implicated in metabolic regulation, particularly in liver and adipose tissues. The drug was primarily investigated for the treatment of obesity, aiming to increase metabolism and fat burning while improving insulin sensitivity. Developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), with origins at the University of Queensland, it reached Phase 2 clinical trials for obesity but development was discontinued after this stage[3][5][6]. Preclinical studies indicated reductions in body fat and reversal of existing obesity without central nervous system side effects[5].
- Other names
- IONIS-FGFR4IONIS-FGFR-4IONIS-FGFR 4
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on IONIS-FGFR4Rx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IONIS-FGFR4Rx.